Search

Your search keyword '"Pella Daniel"' showing total 221 results

Search Constraints

Start Over You searched for: Author "Pella Daniel" Remove constraint Author: "Pella Daniel" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
221 results on '"Pella Daniel"'

Search Results

1. PCSK9 concentrations in different stages of subclinical atherosclerosis and their relationship with inflammation

2. Prevalence of statin intolerance: a meta-analysis

3. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).

4. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

6. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

7. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

8. Retention projection enables accurate calculation of liquid chromatographic retention times across labs and methods

10. The Role of Nutraceuticals in Statin Intolerant Patients

11. Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study

12. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

15. Pre-heart failure at 2D- and 3D-speckle tracking echocardiography: A comprehensive review

16. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients : a position paper from the International Lipid Expert Panel (ILEP)

17. Súlad a nesúlad medzi základnými ukazovateľmi lipidového metabolizmu stanovenými rutinnými laboratórnymi metódami a metódou protónovej nukleárnej magnetickej rezonančnej spektroskopie v náhodne vybranej populačnej vzorke

18. European survey on national harmonization in clinical research

21. Western diets and risk of non-communicable disease

23. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

25. The possible role of machine learning in detection of increased cardiovascular risk patients - KSC MR Study (design).

27. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

28. The possible role of machine learning in detection of increased cardiovascular risk patients – KSC MR Study (design)

29. European survey on national harmonization in clinical research

32. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

33. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

34. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

35. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

38. Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome

39. An open-source simulator for exploring HPLC theory

40. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

41. The Role of Nutraceuticals in Statin Intolerant Patients.

42. Is calculated Apolipoprotein B value a reliable surrogate of its true serum value? Comparison of four equations

43. Rare Presentation of Left Lower Lobe Pulmonary Artery Dissection

47. Age-adjusted mortality rates of neoplastic and circulatory diseases and their demographic factors in Slovak regions during 1996–2013

48. Lipoprotein‐Associated Phospholipase A 2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease

49. Is there is Need for Ubiquinone (CoQ10) Supplementation in Statin- Associated Myopathy?

50. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Catalog

Books, media, physical & digital resources